Biogen Closes Apellis Tender, Consolidating Complement Control Across GA and Nephrology
Biogen’s $5.6 billion tender offer for Apellis Pharmaceuticals expires today, locking in two FDA-approved complement products and positioning the combined entity as the category incumbent in C3-mediated disease before rivals complete their own clinical programs.
The Signal
Biogen’s tender offer for Apellis Pharmaceuticals expired at 11:59 p.m. Eastern Time on May 13, 2026, completing a $5.6 billion acquisition that consolidates SYFOVRE (pegcetacoplan) for geographic atrophy and EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and two rare kidney indications under a single commercial infrastructure. The closing follows HSR Act clearance on May 11, satisfying the final regulatory condition for the Section 251(h) merger. Combined Apellis product net sales reached $689 million in 2025, growing at a mid-to-high teens rate projected at least through 2028, and they now sit alongside Biogen’s felzartamab Phase 3 programs in IgA nephropathy and antibody-mediated rejection.
Why It Matters
The closure is not just a balance-sheet event. It is a category-formation moment for complement-mediated therapeutics. Biogen now controls the only approved C3 inhibitor in two commercially distinct indications and inherits Apellis’s deep C3 biology expertise at the precise moment when the GA therapeutic class is transitioning from early adoption to payer standardization. Competing intravitreal complement programs from Annexon (vonaprument, C1q targeting in ARCHER II) and Regeneron (cemdisiran, C5 siRNA in SIENNA) remain in Phase 3, with no approved rival to SYFOVRE in the GA indication. SYFOVRE’s five-year GALE data showing approximately 1.5-year delay in nonsubfoveal GA progression now belongs to a company with Biogen’s commercial scale and payer relationship depth, which was the missing variable in Apellis’s standalone commercial trajectory. In nephrology, the acquisition accelerates Biogen’s global felzartamab buildout by adding EMPAVELI’s two approved kidney indications as a commercial proof point with prescribers the company has not previously reached.
Annexon and Regeneron bear the most concentrated exposure. Annexon’s vonaprument (C1q-targeting) in the ARCHER II trial now faces a better-resourced incumbent at approval: Biogen’s combined commercial infrastructure and SYFOVRE’s growing long-term dataset will set the bar for payer formulary positioning and retina specialist adoption before vonaprument can complete its primary readout, likely late 2026 or early 2027. The mechanism is formulary entrenchment: payers deciding GA treatment pathways over the next two HEDIS cycles will negotiate against a vertically integrated Biogen, not against a standalone Apellis with limited contracting leverage. For Annexon, the responsible defense is to accelerate any differentiation data on ARCHER II, specifically the subretinal versus nonsubretinal stratification analysis, and get it in front of payer medical directors before Biogen’s rebate infrastructure locks in step-therapy protocols. For Regeneron’s cemdisiran program, the risk is subcutaneous route advantage becoming table stakes rather than a differentiator if Biogen accelerates any delivery-format work on SYFOVRE’s formulation through Apellis’s manufacturing platform.
Mid-cap biotechs with C3 pathway assets outside ophthalmology and nephrology are now better positioned than they were 24 hours ago. Biogen’s acquisition signals that complement biology commands strategic acquisition multiples (140% premium to Apellis’s unaffected share price) and that the acquirer appetite is not limited to CNS or legacy neurology assets. Companies like Omeros, with its OMS906 targeting MASP-3 of the lectin pathway, and Achillion (now part of Alexion/AstraZeneca), which already validated C3 upstream thinking, have competitive data points they can now reprice relative to a validated precedent transaction. The specific mechanism is multiple re-rating: complement-pathway biotechs below $2 billion in market cap with Phase 2 readouts in 2026 or 2027 can now use the Biogen-Apellis precedent as a floor for partnership and acquisition negotiations. The window is the next 90 days, before Biogen’s digestion of Apellis clarifies whether they will become a complement acquirer or a complement operator. The responsible move for these companies is to run their Phase 2 data packages against the Apellis clinical dossier and identify where their mechanism offers complementary, not duplicative, coverage across the C1-C3-C5 cascade axis, then take that package to BD conversations before Biogen’s internal pipeline review closes the inbound window.
The Read
The next 90 days will determine whether the Biogen-Apellis combination accelerates or stalls SYFOVRE commercial momentum. If Biogen’s commercial infrastructure lifts SYFOVRE’s net revenue run rate above the standalone Apellis trajectory, payers will treat the GA indication as a defined standard of care and Annexon’s and Regeneron’s programs will enter an approval environment where step-therapy is already established. Confirmation will appear in Biogen’s Q2 2026 earnings call, scheduled for late July, where management will provide the first post-close revenue guidance for the combined Apellis book. The read will be falsified if SYFOVRE sales growth decelerates in Q2 relative to Q1’s run rate, signaling that Biogen’s integration overhead disrupted Apellis’s commercial momentum rather than accelerating it.
Methodology: Silo 1 (SEC EDGAR) produced this signal. The Apellis SC TO-T/A filing confirmed HSR clearance on May 11 and the May 13 tender offer expiry, scoring Priority 9 as a confirmed M&A closing with direct competitive consequence for the complement inhibitor class. Silo 2 (ETF flows: XLV 5-day outflow of -$600.54M) was scanned and scored a 6: outflows are notable but lack a specific single-day catalyst attribution that would lift them above band noise. Tier 2 was not required given the Silo 1 selection. Competitor sources (Biogen IR, Apellis IR, BioPharma Dive, STAT News) used for corroboration only; primary source is the SEC EDGAR SC TO-T/A and SC 14D9/A filings.